NASDAQ
06.01.26 | 22:00
1,780 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.12.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals GAAP EPS of -$0.37 | 2 | Seeking Alpha | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.10.25 | Zentalis to present azenosertib data at cancer therapeutics conference | 5 | Investing.com | ||
| 01.10.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 85 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.09.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 142 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.08.25 | Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary | 4 | GlobeNewswire (USA) | ||
| 26.08.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08.25 | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.07.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 163 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.06.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 119 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.05.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 185 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.04.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 186 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.03.25 | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 208 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
| 03.03.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 171 | GlobeNewswire (Europe) | SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 03.02.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 187 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule... ► Artikel lesen | |
| 29.01.25 | Pre-market Movers: Silexion Therapeutics, Zentalis Pharmaceuticals, 60 Degrees Pharmaceuticals, Manhattan Associates, Nextracker | 680 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Silexion Therapeutics Corp (SLXN) is up over 65%... ► Artikel lesen | |
| 29.01.25 | Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer | 134 | GlobeNewswire (Europe) | Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,930 | -0,05 % | XFRA 5CV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCUREVAC N.V. O.N.... ► Artikel lesen | |
| MODERNA | 30,220 | -1,02 % | MODERNA: Heute ein Exot dank Impfstoff-Fortschritt. | Das Biotech-Unternehmen schafft heute eine Performance von aktuell + 9,7 %. Abgesehen vom zweiten "Exoten" AXON (+ 6,0 %), wird das Feld Top 10 klar von Halbleiter-Werten dominiert. Für den Antrieb... ► Artikel lesen | |
| VALNEVA | 4,122 | -1,34 % | Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement | Saint-Herblain (France), Pune, (India), December 31, 2025 - Valneva SE ("Valneva" or "the Company"), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company... ► Artikel lesen | |
| NOVAVAX | 6,348 | -0,22 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,421 | +4,47 % | NurExone schafft Grundlage für First-in-Human-Perspektive mit ExoPTEN | ||
| IMMUNITYBIO | 1,870 | +1,88 % | ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe | ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,515 | -1,18 % | Zukunft der Krebstherapie: Warum diese NASDAQ-Aktie jetzt im Januar eine außergewöhnliche Einstiegschance bietet | ||
| ALDEYRA | 3,533 | +1,82 % | Aldeyra Therapeutics: Entwicklungsvorstand tritt bis März 2026 zurück | ||
| IOVANCE BIOTHERAPEUTICS | 2,217 | +1,79 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| GUARDANT HEALTH | 94,98 | -1,14 % | Guardant Health is the top performing healthcare services stock YTD | ||
| COHERUS ONCOLOGY | 1,201 | +2,78 % | Coherus BioSciences: Aktie legt nach Veröffentlichung von Daten zu CCR8-Antikörper zu | ||
| OCULAR THERAPEUTIX | 9,548 | -0,04 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD | Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage... ► Artikel lesen | |
| ESPERION | 3,247 | +1,88 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,394 | -1,45 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.